{{practice}} has been pre-approved to offer Endolift® in {{city}}.
FDA-Cleared Medical Laser Technology
A new structural treatment tier for {{practice}}, and exclusive provider positioning in {{city}}.
Clinical pack
Protocol, published evidence, safety summaries, and patient-positioning materials.
Device evaluation
LASEmaR® 1500 overview, acquisition pathways, and medical-liaison call.
Training pathway
Provider onboarding, protocol review, and clinical implementation planning.
Market position
Shortlist consideration for the {{city}} provider territory.
The Procedure
The Commercial Position
Exclusivity
Selected Endolift® results across face, neck, and body indications.
Your practice passed our pre-approval review.
Verified Clinical Credentials
The lead physician holds active board certification or equivalent clinical qualification in an aesthetic or medical specialty.
Established Patient Base
The practice has a documented patient volume consistent with successful integration of a premium procedure tier.
Positive Patient Reputation
Public review profile reflects consistently high patient satisfaction and clinical outcomes across multiple platforms.
Suitable Treatment Environment
The practice operates a compliant clinical facility appropriate for minor outpatient procedures under local anesthetic.
Aesthetic Procedure Portfolio
The practice already offers injectable, laser, or energy-based treatments, indicating an existing patient population suited to Endolift®.
Geographic Availability
No, or very few, other Endolift®-certified providers are currently operating within your immediate service area.
How Endolift® works - a subdermal laser platform that addresses tissue layers no surface-applied device can reach.
Subdermal Delivery
Immediate Contraction
Collagen Stimulation
Visible Results
Why 1470nm Specifically
LASEmaR® 1500
- Micro-optical fiber delivery for targeted energy
- Real-time tissue interaction with controlled thermal profile
- Ergonomic, compact design for clinical efficiency
- Built-in safety systems and intuitive interface
| Wavelength | 1470 nm |
|---|---|
| Power | Up to 15W |
| Fiber | 200 to 1000 microns |
| Indications | Face, neck, body |
| Downtime | Minimal, 2 to 5 days |
| Clearance | FDA 510(k) K092860 · CE Class IIb · ISO 13485 |
Most non-surgical aesthetic platforms operate from the surface. Endolift® does not.
| Treatment | Depth of Action | Fat Reduction | Collagen Stimulation | Anesthetic | Downtime |
|---|---|---|---|---|---|
| RF Microneedling | Partial subdermal | Limited | Moderate | Topical | 2–5 days |
| HIFU / Ultrasound | Limited subdermal | No | Moderate | None | Minimal |
| Threadlift | Mechanical subdermal | No | Mild | Local | 3–7 days |
| External Laser | Surface only | No | Surface only | None | Varies |
| Surgical Facelift | Full subdermal | Partial | Incidental | General / IV | 2–4 weeks |
| Endolift® | Targeted subdermal | Yes | Strong - histologically confirmed | Local | 2–5 days |
The patients you cannot fully serve today.
- The patient between injectable ceiling and surgical threshold
- The post-weight-loss patient with residual pockets and laxity
- The patient who has plateaued on filler and is starting to look over-corrected
- The early surgical candidate not yet ready for rhytidectomy
- The localized fat presentation resistant to conservative measures
- The atrophic acne scarring patient - rolling, boxcar, and icepick subtypes
A premium structural procedure at outpatient operating cost.
Does Not Cannibalize
Premium Tier Positioning
Patient Retention
The procedure your patients are already searching for.
Patients searching "Endolift near me" in {{city}} today find limited or no certified options. {{practice}}'s pre-approval places your practice at the front of this curve.
Published clinical evidence includes peer-reviewed RCT, observational, and prospective data.
Randomized Controlled Trial
Bernardini et al. - Lasers in Surgery and Medicine, 2021. 96 subjects.
Prospective RCT evaluating Endolift® for facial and neck rejuvenation. Primary endpoints: tissue laxity and patient satisfaction at 6 months. Results consistent with clinically significant improvement in the treated cohort.
Prospective Observational
Tretti Clementoni et al. - Journal of Cosmetic and Laser Therapy, 2019.
Prospective evaluation of submental and jowl treatment. Histological analysis at 30 days post-procedure confirms new collagen fiber formation and adipocyte disruption consistent with the proposed mechanism of action.
Histological Analysis
Biopsied tissue analysis - multiple independent sites. 1, 3, 6, 12-month timepoints.
Serial biopsy data from treated and control sites. Findings include statistically significant increases in collagen type I density, new elastin deposition, and measurable reduction in adipocyte volume at 12-month follow-up.
Retrospective Cohort
Scuderi et al. - Aesthetic Plastic Surgery, 2022. Multi-center data.
Multi-center retrospective review of 140 patients treated across face, neck, and body indications. Safety profile consistent with outpatient delivery; no reports of serious adverse events attributable to device at 6-month follow-up.
Systematic Review
Independent systematic review of 1470nm subdermal laser technology - published literature to 2023.
The full clinical evidence package – including all cited studies, methodology summaries, and safety data tables – is included in the Endolift® Clinical Pack. Histological evidence of new collagen formation is a consistent finding across independent research groups. All clinical claims on this page defer to published literature; individual patient outcomes cannot be guaranteed.
Histological evidence of neo-collagenesis and elastin deposition is a consistent finding across independently conducted biopsy studies. All claims on this page refer to published data and do not constitute a guarantee of individual outcomes.
What is included with your pre-approved Endolift® provider package.
- LASEmaR® 1500 device - compact desktop unit, fully configured
- Single-use sterile fiber kit - RING (360°) and FLAT (directional) options
- Comprehensive, supervised live clinical training at your practice
- Official Endolift® practitioner certification on completion
- A complete marketing kit, designed to launch fast
- Listing in the public Endolift® practitioner directory
- Endolift® Online Academy - clinical reference video library
- Endolift® Practitioner Community - private peer network
- Endolift® Masters Series - advanced technique training
- Ongoing US-based clinical and commercial support from MediPrisma LLC
Acquisition note: Outright purchase and finance lease options available. Finance through Reliant Capital – credit decisions typically within 2–4 hours. Onboarding from confirmed acquisition to first independent patient treatment: typically 3–6 weeks depending on scheduling.
Why your invitation is time-limited.
- Pre-approval is specific to {{practice}} and cannot be transferred
- One pre-approved invitation per practice per review cycle
- Expired invitations require re-entry to the qualification review
- Future cycles in {{city}} are not guaranteed within any specific timeframe
Accepting the invitation opens a structured evaluation pathway.
Receive the Clinical Pack
Discuss Clinical Fit
Our US Medical Liaison contacts you within few business days. Indication selection, workflow integration, and menu positioning.
Review Acquisition Options
Plan Training & Launch
Common questions from medical directors.
The LASEmaR® 1500 is FDA-cleared under 510(k) reference K092860. It holds CE Mark Class IIb certification and is manufactured under ISO 13485 quality management standards at Eufoton® S.r.l., Trieste, Italy. Device clearance, certification documents, and the current FDA database entry are available upon request.
Training begins with a theory and protocol session covering anatomy, energy delivery parameters, indication selection, and contraindications. This is followed by supervised live clinical sessions – the number varies by prior experience and indication range – with certification issued on confirmation of competence. Training takes place on-site at your own practice. The full training pathway is outlined in the Clinical Pack.
No. Endolift® serves a patient cohort that existing transcutaneous energy devices cannot reach – specifically those requiring subdermal fat reduction and structural tissue remodeling. RF and HIFU generate thermal energy from the surface, with limited subdermal penetration and no direct adipolysis. Endolift® operates subdermally via optical fiber. The procedures are complementary, not competing. Practices typically find that offering Endolift® creates a premium structural tier that enhances, rather than replaces, their existing energy-device revenue.
Published clinical data and real-world practice report typical downtime of 2–5 days, characterized by minor swelling (due to local anesthetic) and sometimes mild bruising at the entry point and treatment area. Patients are generally able to resume light activity immediately. Recovery varies by treatment area, energy settings, and individual patient factors. Precise downtime expectations for specific indication combinations are detailed in the Clinical Pack.
Published multi-center retrospective data (Scuderi et al., 2022, n=140) reports no serious adverse events attributable to the device at 6-month follow-up. Expected events – temporary swelling, bruising, and mild discomfort at the entry point – resolved within the standard recovery window across the published literature. The full safety data table and adverse event profile are included in the Clinical Pack. Endolift® is a Class IIb medical device – appropriate clinical training and patient selection are prerequisites to safe delivery.
Endolift® consistently ranks among the highest ROI procedures in the non-surgical aesthetics market. Most practices recoup their full device investment within 20 to 25 procedures, after which each session generates substantial net revenue. Device pricing and finance options are discussed directly during the acquisition conversation. Finance options through Reliant Capital are available for qualifying practices, with credit decisions typically within 2–4 hours.
This invitation is addressed to the medical director, lead physician, or principal of {{practice}}. If you are not that person, please forward this page link directly to them today. The link can be shared internally. If the right person at your practice has not seen this invitation before the expiration date, the slot will be released.
Accept your pre-approved Endolift® invitation.
For Medical Professionals Only.
Endolift® is distributed in the United States by MediPrisma LLC. The LASEmaR® 1500 is designed and manufactured by Eufoton® S.r.l., Trieste, Italy. FDA-cleared, 510(k) reference K092860. CE Mark Class IIb. ISO 13485. This page is directed exclusively at licensed medical professionals. Results vary by patient, indication, practitioner experience, and anatomical site. Individual outcomes cannot be guaranteed. All clinical claims on this page defer to published peer-reviewed literature. Endolift®, EndoliftX®, and LASEmaR® are registered trademarks of Eufoton® S.r.l. This invitation is non-transferable and addressed to the named practice only.